



Interim Report Q1 2026

Announcement no. 24/2026

Sveinn Sölvason, President and CEO, comments:

“Sales in the first quarter of 2026 reached USD 232 million, representing reported growth of 15% and organic growth of 4%. We delivered strong performance in Prosthetics & Neuro Orthotics, driven by continued momentum and solid volume growth across regions and categories. Bracing & Supports delivered moderate growth, while Patient Care experienced a softer quarter, largely driven by timing effects in Europe. We are seeing more favorable trends in the U.S. Patient Care business and remain well on track with our strategic initiatives to support growth in the coming quarters across our global Patient Care business.

EBITDA margin was 17%, reflecting the impact of external factors such as FX and tariffs. We continue to execute with discipline and remain focused on delivering margin expansion as growth accelerates.

We reiterate our full-year guidance of 5-8% organic sales growth and an EBITDA margin of 20-22%.”

Highlights Q1 2026

- Sales amounted to USD 232 million with 15% reported growth and organic growth was 4%, on par with Q1 2025.
- Prosthetics & Neuro Orthotics sales grew by 9% organic, Bracing & Supports (B&S) sales grew by 1% organic, while Patient Care was down 1%.
- Gross profit margin was 62%, compared to 63% in Q1 2025. The lower Gross profit margin was positively impacted by strong sales in P&NO but offset by items such as FX and US tariffs.
- EBITDA was USD 40 million, and EBITDA margin was 17% of sales, compared to 18% in Q1 2025. The EBITDA margin is down between quarters mainly due to FX headwinds and tariffs.
- Net profit was USD 15 million and increased by 21% compared to Q1 2025 with a net profit margin of 6%. The increase was driven by growing operating results and favorable impact from net financial expenses.
- Free cash flow amounted to USD 4 million or 2% of sales, compared to 4% of sales in Q1 2025. Free cash flow benefitted from lower CAPEX but negatively impacted from changes in net working capital. The free cash flow is seasonally low in Q1.
- NIBD/EBITDA before special items was 2.4x at the end of Q1 2026, which is within our target range of 2-3x EBITDA. The share buyback program is ongoing and during Q1 2026, Embla Medical bought back 556,103 shares at a market value of USD 2.6 million.

Other highlights

- On March 13, 2026, Embla Medical announced the completion of the capital reduction of ISK 2,441,257 nominal value registered with the Icelandic Register of Enterprise. Following the share cancellation Embla Medical’s share capital is ISK 428,000,000 nominal value.

2026 Outlook

- Organic sales growth guidance is unchanged at 5-8%.
- EBITDA margin before special items guidance is unchanged at 20-22%

	Q1 2026	Q1 2025	FY Guidance 2026
Sales growth, organic	4%	4%	5-8%*
EBITDA margin	17%	18%	20-22%*

*Potential impact from US trade tariffs continues to be an uncertain element to quantify given the frequent changes in the global tariff environment. Consequently, we deem it too speculative to quantify and guide an exact impact from potential tariffs on Embla Medical’s financial results, but some absorption of tariffs is assumed in the guidance.

	Q1 2026	Q1 2025	FY 2025	FY 2024	FY 2023	FY 2022
Income Statement						
Net sales	232	203	929	855	786	719
Gross profit	143	128	579	535	486	440
Operating expenses (excl. other income / exp.)	120	106	454	422	398	373
EBITDA	40	36	186	169	139	114
EBITDA before special items	40	36	186	173	139	128
EBIT	24	22	125	113	89	65
Net profit	15	12	84	69	59	43
Sales Growth						
Sales growth USD	% 15	1	9	9	9	0
Growth breakdown:						
Organic growth	% 4	4	6	6	9	4
Currency effect	% 7	(2)	2	0	(1)	(7)
Acquired business	% 3	0	1	3	1	3
Balance Sheet						
Total assets	1,709	1,589	1,730	1,539	1,386	1,325
Equity	905	802	896	781	705	636
Net interest-bearing debt (NIBD)	459	437	439	414	395	404
Cash Flow						
Cash generated by operations	20	23	178	160	126	92
Free cash flow	4	8	100	77	52	35
Key Ratios						
Gross profit margin	% 62	63	62	63	62	61
EBIT margin	% 10	11	13	13	11	9
EBITDA margin	% 17	18	20	20	18	16
EBITDA margin before special items	% 17	18	20	20	18	18
Equity ratio	% 53	50	52	51	51	48
Net debt to EBITDA before special items*	2.4	2.5	2.4	2.4	2.8	3.2
Effective tax rate	% 23	23	23	24	23	23
Return on equity*	% 10	9	10	9	9	7
CAPEX / Net sales	% 2.3	3.0	3.4	4.6	5.4	3.6
Market						
Market value of equity	1,745	1,742	2,202	2,125	1,713	2,035
Number of shares in millions	428	428	430	428	421	423
Basic EPS in US cents	3.4	2.8	19.6	16.2	14.0	10.3
Diluted EPS in US cents	3.4	2.8	19.6	16.2	14.0	10.3

* Financial ratios are based on operations for the preceding 12 months.

Management's report

Financial performance

Sales

Sales in Q1 2026 amounted to USD 232 million, compared to USD 203 million in Q1 2025, corresponding to 4% organic growth, 8% local currency growth (including 3%-points from M&A) and a 15% reported growth (USD growth). The currency impact on sales was positive by 7% in the quarter.

Sales increased by 4% organic

Reported sales growth of 15%

Sales by geographical segment (USD million)	Q1 2026	Organic growth	Δ Acq.	Δ Curr. effect	USD growth
EMEA	124	4%	6%	12%	22%
Americas	89	3%	0%	1%	4%
APAC	19	14%	0%	7%	21%
Total	232	4%	3%	7%	15%

Sales by business segment (USD million)	Q1 2026	Organic growth	Δ Acq.	Δ Curr. effect	USD growth
Prosthetics & Neuro Orthotics	136	9%	6%	7%	22%
Bracing & Supports	37	1%	0%	5%	5%
Internal product sales	(10)	4%	1%	7%	12%
External sales	163	7%	5%	7%	18%
Patient Care	70	-1%	0%	8%	7%
Total	232	4%	3%	7%	15%

Growth driven by Prosthetics & Neuro Orthotics

Growth in Q1 2026 was driven by continued momentum in Prosthetics & Neuro Orthotics, supported by solid volume growth across regions and categories.

In the Americas, organic sales growth was 3% for the quarter, supported by strong performance in Prosthetics & Neuro Orthotics, driven by recently launched innovation in Bionics and Feet. Neuro Orthotics have begun to ramp up in the US, with a more meaningful contribution expected over the year as we broaden the launch of our first bionic knee joint, which received a reimbursement code last summer in this important market. Sales in Bracing & Supports were flat for the quarter. B&S sales continue to be affected by shifting market dynamics, increased price sensitivity, and competitive pressure. With focused initiatives and new product launches, growth is expected in 2026, with a greater weighting toward the second half of the year. In Patient Care, performance recovered in Q1, in line with the initiatives implemented during the second half of 2025, following a period of lower sales growth in the region.

In EMEA, organic sales growth was 4% in Q1 2026, supported by strong regional momentum with broad-based contribution from Bionics, Feet, and other key product categories. Neuro Orthotics continues to progress across several European markets, reflecting our strategy to expand the Fior & Gentz portfolio internationally. Bracing & Supports sales were soft, consistent with trends seen in the Americas, with better performance expected as the year progresses. In Patient Care, sales were softer in the quarter, primarily due to timing effects in several European markets, partly related to Easter vacations overlapping March, but also following a strong fourth quarter in 2025. As timing effects normalize, Patient Care is expected to return to consistent sales performance in line with the market during 2026.

In APAC, sales growth was strong in the first quarter, with 14% organic growth driven by strong performance across all three segments. Growth in Prosthetics & Neuro Orthotics reflected strength across key countries and product categories. Bracing & Supports delivered strong growth, particularly in Asia as well as in Australia and New Zealand. Sales performance in Patient Care remained solid in Australia.

Sales in Bracing & Supports were soft in 2025 with some regional variances. Sales continue to be impacted by shifting market dynamics and price sensitivity causing partial loss of business, in addition to increasing competitive pressure. Growth is expected in 2026 with focused initiatives and new product launches.

As previously communicated, Patient Care delivered lower than expected growth in 2025, mainly in EMEA and the Americas. This was partly driven by softness and timing in patient volumes, as well as internal change initiatives, including the ForMotion rebranding, system integrations, and other change initiatives that temporarily impacted performance. Several initiatives were implemented in Patient Care during the second half of 2025, with a focus on strengthening performance management to support growth and profitability. In the Americas, these initiatives are starting to show positive results, while Europe was impacted in the quarter by timing effects such as Easter. Management remains confident that the Patient Care business in both Americas and Europe will deliver in line with the structural growth of the O&P industry in 2026. Furthermore, the initiatives show a positive impact on profitability in Patient Care.

Operations

Gross profit margin of 62% in Q1 2026

Gross profit in Q1 2026 amounted to USD 143 million or 62% of sales, compared to USD 128 million or 63% of sales in Q1 2025. The lower Gross profit margin was positively impacted by strong sales in P&NO but offset by items such as FX and US tariffs.

OPEX ratio of 52% in Q1 2026

Operating expenses (OPEX)

OPEX amounted to USD 120 million or 52% of sales in Q1 2026, compared to USD 106 million or 52% of sales in Q1 2025. OPEX grew 3% organic (below sales growth) in line with continued focus on cost control.

EBITDA margin of 17% in Q1 2026

EBITDA

EBITDA amounted to USD 40 million or 17% of sales, compared to EBITDA of USD 36 million or 18% of sales in Q1 2025. The EBITDA margin is down between quarters mainly due to FX headwinds and tariffs.

The negative effects on EBITDA margin from changes in currencies amounted to roughly 50 basis points net of hedging in Q1 when compared to the same period in 2025.

Financial items, income tax and net profit

Effective tax rate of 23% in Q1 2026

Net financial expenses in Q1 2026 amounted to USD 5 million, compared to USD 7 million in Q1 2025. Lower net financial expenses are driven by lower financial expenses and positive changes in net exchange differences.

Net profit margin of 6% in Q1 2026

Income tax amounted to USD 4 million in Q1 2026, corresponding to a 23% effective tax rate, compared to USD 4 million in Q1 2025, corresponding to a 23% effective tax rate.

Net profit grew by 21% in Q1 2026 amounted to USD 15 million or 6% of sales, compared to USD 12 million or 6% of sales in Q1 2025. Growth in net profit is driven by growing operating results and favorable changes in net financial expenses.

Diluted earnings per share in Q1 2026 amounted to 3.4 US cents, compared to 2.8 in Q1 2025.

Cash flow

Cash generation of USD 20M in Q1 2026

Cash generated by operations

Cash generated by operations amounted to USD 20 million or 8% of sales in Q1 2026, compared to USD 23 million or 11% of sales in Q1 2025. Cash generated by operations was positively impacted by growing operating results but negatively impacted by timing of changes in net working capital.

CAPEX was 2% of sales in Q1 2026

Capital expenditures

Capital expenditures in Q1 2026 amounted to USD 5 million or 2% of sales, compared to USD 6 million or 3% of sales in Q1 2025. CAPEX was below normalized levels of 3-4% of sales due to timing of investments.

Free cash flow was 2% of sales in Q1 2026

Free cash flow

Free cash flow in Q1 2026 amounted to USD 4 million or 2% of sales, compared to USD 8 million or 4% of sales in Q1 2025. Q1 each year is seasonally low in terms of cash flow generation. In addition, free cash flow was weak in the quarter, benefitting from lower CAPEX but negative impact from changes in net working capital.

Cash and undrawn facilities amounted to USD 185 million

Bank balances and cash equivalents

Bank balances and cash equivalents amounted to USD 94 million at the end of Q1 2026 and USD 92 million of existing facilities were undrawn. Bank balances and cash equivalents in addition to undrawn credit facilities at the end of Q1 2026, therefore, amounted to USD 185 million.

Capital structure

NIBD/EBITDA before special items at 2.4x

Net-interest bearing debt

Net interest-bearing debt, including lease liabilities, amounted to USD 459 million at quarter-end Q1 2026 compared to USD 437 million at quarter-end Q1 2025. Net interest-bearing debt to EBITDA before special items corresponded to 2.4x at quarter-end Q1 2026, within the target range of 2.0-3.0x.

Share buybacks of USD 2.6M in Q1 2026

Share buybacks and treasury shares

The purpose of the program is to reduce the Company's share capital and adjust the capital structure with a desired capital level of 2.0-3.0x net interest-bearing debt to EBITDA before special items, by distributing capital to shareholders in line with the Company's Capital Structure and Capital Allocation Policy.

During Q1 2026, Embla Medical bought back 556,103 shares at a market value of USD 2.6 million compared to 295,653 shares at a market value of approximately USD 1 million Q1 2025. At the end of Q1 2026, treasury shares totaled 788,422.

Financial guidance

Guidance	Guidance FY 2026	Actual FY 2025
Sales growth, organic	5-8%	6%
EBITDA margin	20-22%	20%
For modelling purposes		
CAPEX as % of sales	3-4%	3%
Effective tax rate	23-24%	23%

For 2026 organic sales growth is expected to be in the range of 5-8%. We anticipate continued strong momentum in our Prosthetics & Neuro Orthotics business across regions supported by solid contributions from our fast-growing bionic portfolio and recently launched innovations in addition to upcoming launches in 2026. Some positive impact from the US Medicare Coverage Expansion is also expected to contribute to sales supported by our existing portfolio of microprocessor knee (MPK) solutions, which in the future will be complemented by a dedicated K2 MPK solution to better serve the least mobile users in the low active K2 patient population.

In Neuro Orthotics we expect to see the increasing effects from the ongoing roll out of our Neuro Orthotics offerings (Fior & Gentz) into new markets leveraging our global commercial infrastructure and ForMotion footprint within O&P Clinics. Albeit growing from a low base we expect to see solid growth in the EMEA region with some contributions expected in Americas in the course of 2026 as we prepare ramp-up for a broader launch of our first bionic knee joint “NEURO HiTRONIC MPKAFO”, which received a reimbursement code last summer in the important US market.

In Patient Care, we expect growth to gradually improve during 2026 with the aim of eventually returning to consistent sales performance in line with market. Growth in 2026 is expected to be driven by volume growth, increased efficiency supported by effects from the initiatives implemented across our Patient Care business in the second half of 2025. Focus will be on strengthening growth and profitability and benefiting from the structural growth in the O&P industry our product business has observed in recent periods.

Lastly, Bracing & Supports is expected to grow approximately in line with market growth. We assume solid growth in selected key regions supported by expected launches of new product categories but also with continued competitive pressure in selected markets.

EBITDA margin is expected in the range of 20-22% for 2026 compared to 20% in 2025. The EBITDA margin is expected to be positively impacted by solid sales performance, a favorable product mix from increased sales of our high-end solutions, continued efficiency gains in manufacturing, increasing profitability in Patient Care, and cost control in SG&A.

At current foreign exchange rates, keeping all other factors constant, the EBITDA margin is expected to be negatively impacted by about 10 basis points net of hedging in 2026 when compared to 2025.

Foreign exchange

Sales are particularly exposed to fluctuations in the EUR/USD exchange rate. Additionally, the ISK has a relatively high impact on operating results as part of manufacturing, R&D and some corporate functions are based in Iceland, while sales in ISK are minimal. A breakdown of sales and costs by main currencies can be found in note 4 of the accompanying Condensed Consolidated Financial Statements.

All else being equal, a +/- 5% movement in EUR/USD is estimated to have an annual impact on EBITDA in the range of +/- USD 3.5-4.5 million when unhedged. The same movement in ISK/USD is estimated to have an annual impact on EBITDA in the range of +/- USD 4.0-5.0 million when unhedged. Embla Medical utilizes forward contracts to hedge approximately 50% of the estimated net currency exposure to ISK.

Currency overview USD	EUR	ISK
Average exchange rate FY 2025	1.130	0.0078
Average exchange rate in Q1 2026	1.167	0.0081
Opening rate April 27 2026	1.172	0.0081
Estimated average exchange rate for FY 2026*	1.171	0.0081
Change in estimated exchange rate FY 2026 compared to last year's average	4%	4%

*Estimated average exchange rate is calculated as exchange rate (open) on April 7, 2026, for the remainder of the year

Other highlights

Section 232 investigations on MedTech equipment

On 26 September 2025, the US Department of Commerce published a notice for a public consultation on a possible Section 232 Investigation concerning robotics/industrial machinery as well as personal protective equipment (PPE), medical consumables and medical equipment including devices such as hearing aids, prosthetics, orthopedic appliances, ventilators and respirators etc. The objective is to determine the effects on the US national security of imports of these goods. We are currently assessing the scope and potential implications of the Section 232 investigation and the potential trade restrictions that might result from this. As several factors remain uncertain at this stage, we deem it to be too premature to discuss potential impact until more clarity has been revealed.

ForMotion: Rebranding close to completion

In Q1 2026 several patient care facilities in the United States were rebranded to ForMotion. The global rebranding roll-out is more than 90% complete and expected to conclude during the second quarter 2026.



Product launches during the last 12 months

Launch quarter	Segment	Product name	Product description
Q1 2026	Prosthetics Vent for sockets	AeroFit® Vent	<p>AeroFit combines a 3D-printed Seal-In liner with a vented socket. The silicone liner increases comfort by reducing humidity accumulation, leaving the limb feeling drier and healthier. The unique design of AeroFit uses the user's own movement to expel air from the socket, promoting airflow and leaving the skin feeling drier.</p> <p>Perceived skin health of the residual limb is improved by the micro-hole pattern, meshed silicone structure, and the AeroFit Seal-In liner fabric, which wicks humidity away.</p>
Q4 2025	Prosthetics Bionic knee	Power Knee™ Update (Össur)	<p>Power Knee™ controls have been updated to deliver functional improvements that enhance mobility and adoption of powered solutions. Synchronous Control™ provides natural, powered motion that adapts seamlessly to each step at any walking speed. Sit-to-stand assistance can now be smoothly ramped and tailored to user preference, while improved stair and stumble-recovery functions deliver more natural transitions and support when it is needed most.</p>
Q2/Q3 2025	Prosthetics Bionic foot	Odyssey® iQ (College Park)	<p>The new Odyssey® iQ microprocessor foot is hydraulically dampened, lightweight, and low-profile. With an IP67 rating, long-lasting battery, and fast responses, it accommodates a wide range of users and activities.</p>
Q2 2025	Prosthetics Socket	AeroFit® (Össur)	<p>AeroFit® is a breathable prosthetic interface system combining a vented socket with a 3D-printed silicone liner to significantly reduce humidity inside the prosthesis. Excess moisture is a common cause of discomfort and skin issues for lower-limb.</p>

Conference call and financial calendar

Conference call details

Embla Medical will host a conference call on April 28, 2026, at **9:00 CET / 7:00 GMT / 3:00 ET**.

To actively participate in the telephone conference, please use the dial-in details provided below:

DK: +45 78 76 84 90

UK: +44 20 3769 6819

US: +1 646 787 0157

Participant access code: 274982

The webcast will be available through following link: [Embla Medical Q1 2026 webcast](#)

Financial calendar and events 2026

April 28, 2026	Interim Report Q1 2026
April 28, 2026	Q1 2026 Presentation & Q&A, virtual (HC Andersen Capital)
April 28, 2026	Q1 2026 Investor Road Show, Copenhagen (ABG)
April 29, 2026	Q1 2026 Investor Road Show, Frankfurt (Berenberg)
April 29, 2026	Q1 2026 Investor Road Show (virtual), Benelux (SEB)
April 30, 2026	Q1 2026 Investor Road Show, London (DNB Carnegie)
May 4, 2026	Q1 2026 Investor Road Show, Reykjavik (Embla HQ)
May 21, 2026	Aktie-Info Investor Event (retail), Copenhagen
May 28, 2026	DNB Carnegie Healthcare Day, Paris
July 21, 2026	Interim Report Q2 2026
August 26, 2026	Økonomisk Ugebrev Investor Conference, Copenhagen
September 15, 2026	Berenberg Nordic Seminar, Madrid
September 23, 2026	Bank of America Global Healthcare Conference 2026, London
October 20, 2026	Interim Report Q3 2026
November 10, 2026	Berenberg Nordic Seminar, Paris
November 18-19, 2026	Jefferies Global Healthcare Conference, London
November 24, 2026	Aktie-Info Investor event (retail), Kolding
November 26, 2026	Danske Bank Winter Seminar, Copenhagen
February 2, 2027	Q4 Report 2026 & 2026 Annual Report

For further information

Contact details

Klaus Sindahl, Head of Investor Relations

+45 5363 0134

ksindahl@emblamedical.com

Embla Medical corporate announcements by e-mail

If you wish to receive Embla Medical's e-mail alerts, please register on our website:

<https://emblamedical.com/investor-relations>

Forward-looking statements

This press release includes "forward-looking statements" which involve risks and uncertainties that could cause actual results to differ materially from results expressed or implied by these statements. Össur hf. undertakes no obligation and does not intend to update these forward-looking statements to reflect events or circumstances occurring after this press release. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement.



Embla Medical hf.

**Condensed Interim Consolidated
Financial Statements**

31.3.2026

Embla Medical hf

Grjóthálsi 5

110 Reykjavík

Id-no. 560271-0189

Statement by the Board of Directors and President and CEO

The Condensed Interim Consolidated Financial Statements of Embla Medical hf. for the period from 1 January 2026 to 31 March 2026 consist of the Financial Statements of Embla Medical hf. and its subsidiaries (together referred to as “the Company” or “Embla Medical”). The Condensed Interim Consolidated Financial Statements are prepared in accordance with International Financial Reporting Standards for Interim Financial Reporting, IAS 34, as adopted by the EU. The Condensed Interim Consolidated Financial Statements have not been audited or reviewed by the Company's auditors.

The total Net sales of the Company amounted to USD 232.4 million and the Net profit amounted to USD 14.5 million. Total assets of the Company amounted to USD 1,709.1 million at the end of period, liabilities were USD 804.5 million and equity was USD 904.6 million.

In our opinion, these Condensed Interim Consolidated Financial Statements present all the information necessary to give a true and fair view of the Company's financial position as at 31 March 2026 and its financial performance and cash flow for the period ended 31 March 2026.

The Board of Directors and the President and CEO of Embla Medical hf. hereby confirm the Condensed Interim Consolidated Financial Statements for the period from 1 January 2026 to 31 March 2026 with their signatures.

Reykjavík, 28 April 2026

Board of Directors

Niels Jacobsen
Chairman of the Board

Svafa Grönfeldt
Vice Chairman of the Board of Directors

Arne Boye Nielsen
Member of the Board of Directors

Alberto Esquenazi
Member of the Board of Directors

Tina Abild Olesen
Member of the Board of Directors

Caroline Vagner Rosenstand
Member of the Board of Directors

President and CEO

Sveinn Sölvason

Consolidated Income Statement

All amounts in USD '000	Notes	Q1 2026	Q1 2025
Net sales	3	232,395	202,786
Cost of goods sold		(89,343)	(75,020)
Gross profit		143,052	127,766
Other income / (expenses)		1,341	367
Sales and marketing expenses		(87,031)	(78,057)
Research and development expenses		(12,916)	(10,569)
General and administrative expenses		(20,465)	(17,280)
Earnings before interest and tax (EBIT)		23,981	22,227
Financial income		562	674
Financial expenses		(4,864)	(5,250)
Net exchange rate difference		(941)	(2,606)
Net financial expenses		(5,243)	(7,181)
Share in net profit of associates		221	613
Earnings before tax (EBT)		18,959	15,659
Income tax		(4,453)	(3,631)
Net profit		14,506	12,027
Attributable to:			
Owners of the Company		14,457	12,159
Non-controlling interests		49	(131)
Net profit		14,506	12,027
Earnings per share			
Basic earnings per share (US cent)		3.4	2.8
Diluted earnings per share (US cent)		3.4	2.8

Consolidated Statement of Comprehensive Income

All amounts in USD '000	Q1 2026	Q1 2025
Net profit	14,506	12,027
Items that may be reclassified subsequently to profit or loss:		
Change in cash flow hedges	1,102	(79)
Exchange difference on translating foreign operations	(3,309)	8,541
Income tax	(1,214)	1,422
Other comprehensive income, net of income tax	(3,421)	9,883
Total comprehensive income	11,085	21,910
Attributable to:		
Owners of the Company	11,036	22,042
Non-controlling interests	49	(131)
Total comprehensive income	11,085	21,910

Consolidated Balance Sheet

Assets

All amounts in USD '000	Notes	31.3.2026	31.12.2025
Property, plant and equipment	5	78,875	80,215
Right of use assets	6	160,452	162,514
Goodwill	7	828,211	835,560
Other intangible assets	8	104,193	106,908
Investment in associates		28,254	27,950
Other financial assets		3,920	3,966
Deferred tax assets		54,531	55,380
Non-current assets		1,258,435	1,272,493
Inventories		166,423	165,617
Accounts receivable		140,633	144,782
Other financial assets		750	0
Other assets		49,195	45,092
Cash and cash equivalents		93,658	102,507
Current assets		450,659	457,998
Total assets		1,709,095	1,730,491

Consolidated Balance Sheet

Equity and liabilities

All amounts in USD '000	31.3.2026	31.12.2025
Issued capital and share premium	95,854	98,470
Other reserves	(54,246)	(50,494)
Retained earnings	857,708	842,572
Shareholders equity	899,316	890,549
Non-controlling interest	5,245	5,254
Total equity	904,561	895,803
Borrowings	212,158	292,174
Lease liabilities	151,536	153,499
Deferred tax liabilities	37,950	39,788
Provisions	7,823	8,723
Deferred income	11,279	11,346
Other financial liabilities	10,700	19,588
Non-current liabilities	431,446	525,117
Borrowings	161,103	67,678
Lease liabilities	28,142	28,218
Accounts payable	33,991	32,825
Income tax payable	21,678	21,322
Provisions	16,026	16,315
Accrued salaries and related expenses	51,375	59,550
Other financial liabilities	20,540	35,673
Other liabilities	40,233	47,989
Current liabilities	373,087	309,571
Total liabilities	804,533	834,688
Total equity and liabilities	1,709,095	1,730,491

Consolidated Statement of Cash Flow

All amounts in USD '000	Notes	Q1 2026	Q1 2025
Earnings before interest and tax (EBIT)		23,981	22,227
Depreciation and amortization	5, 6, 8	15,848	14,240
Change in inventories		(1,969)	(8,093)
Change in receivables		(1,416)	(3,635)
Change in payables		(14,631)	(1,678)
Change in provisions		(1,130)	178
Other operating activities		(1,083)	(36)
Cash generated from operations		19,600	23,203
Interest received		556	654
Interest paid		(4,742)	(5,100)
Income tax paid		(6,160)	(4,946)
Net cash generated from operating activities		9,254	13,811
Purchase of fixed and intangible assets	5, 8	(5,382)	(6,172)
Acquisition of subsidiaries, net of cash in acquired entities		(281)	0
Payment of contingent consideration and deferred payments		(21,935)	(3,239)
Other investing activities		152	(2,231)
Cash flows used in investing activities		(27,446)	(11,641)
Changes in revolving credit facility		19,496	8,706
Payments of lease liabilities		(7,385)	(6,460)
Purchased treasury shares		(2,616)	(1,277)
Cash flows generated from financing activities		9,494	969
Net change in cash		(8,698)	3,139
Exchange rate effects on cash held in foreign currencies		(151)	2,468
Cash and cash equivalents at beginning of period		102,507	86,163
Cash and cash equivalents at end of period		93,658	91,770

Consolidated Statement of Changes in Equity

All amounts in USD '000	Share capital	Share premium	Other reserves	Retained earnings	Shareholders equity	Non-controlling interests	Total equity
Balance at 1 January 2025	4,829	88,635	(75,390)	759,112	777,186	3,513	780,699
Net profit				12,159	12,159	(131)	12,027
Change in cash flow hedges			(63)		(63)		(63)
Transl. diff. of shares in subsidiaries			9,946		9,946		9,946
Total comprehensive income	0	0	9,883	12,159	22,042	(131)	21,910
Share contract charge			344		344		344
Share contract vested/expired			(2,454)	2,454	0		0
Purchase of treasury shares	(2)	(1,275)			(1,277)		(1,277)
Change in non-controlling interests				(219)	(219)	219	0
Balance at 31 March 2025	4,827	87,361	(67,617)	773,505	798,076	3,601	801,677
Balance at 1 January 2026	4,836	93,634	(50,494)	842,572	890,549	5,254	895,803
Net profit				14,457	14,457	49	14,506
Change in cash flow hedges			882		882		882
Transl. diff. of shares in subsidiaries			(4,303)		(4,303)		(4,303)
Total comprehensive income	0	0	(3,421)	14,457	11,036	49	11,085
Share contract charge			348		348		348
Share contract vested/expired			(679)	679	0		0
Purchase of treasury shares	(4)	(2,612)			(2,616)		(2,616)
Balance at 31 March 2026	4,832	91,022	(54,246)	857,708	899,316	5,245	904,561



Notes to the Condensed Consolidated Financial Statements

1. Summary of Material Accounting Policies

Statement of compliance

The Condensed Interim Consolidated Financial Statements are prepared in accordance with International Financial Reporting Standard (IFRS) for Interim Financial Reporting, IAS 34, as adopted by the EU. The Condensed Interim Consolidated Financial Statements are presented in accordance with new and amended IFRS accounting standards and interpretations (IFRIC) effective for the period. New and amended IFRS accounting standards, effective for the current year, had minor impact on the Company's Consolidated Financial Statements. The Company has not early applied new and revised IFRS accounting standards that have been issued but are not yet effective. The Financial Statements are presented in USD, which is the Company's functional currency. They do not include all of the information required for full Annual Consolidated Financial Statements and should be read in conjunction with the Company's Annual Consolidated Financial Statements for the period ended 31 December 2025. The Company's Annual Consolidated Financial Statements can be found on the Company's website www.emblamedical.com.

Basis of preparation

The Condensed Interim Consolidated Financial Statements have been prepared under the historical cost basis except for certain financial instruments that are measured at fair value. Historical cost is generally based on the fair value of the consideration given in exchange for assets. The Condensed Interim Consolidated Financial Statements are presented in USD and all values are rounded to the nearest thousand ('000), except when otherwise indicated. This rounding may impact totals. The accounting policies adopted are consistent with those followed in the preparation of the Company's Annual Consolidated Financial Statements for the period ended 31 December 2025.

Notes to the Condensed Consolidated Financial Statements

2. Quarterly statements

	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025
Net sales	232,395	256,691	236,795	232,418	202,786
Cost of goods sold	(89,343)	(98,625)	(88,559)	(87,931)	(75,020)
Gross profit	143,052	158,066	148,236	144,487	127,766
Gross profit margin	62%	62%	63%	62%	63%
Other income / (expenses)	1,341	175	(382)	447	367
Sales and marketing expenses	(87,031)	(92,194)	(81,400)	(82,529)	(78,057)
Research and development expenses	(12,916)	(11,948)	(11,489)	(11,851)	(10,569)
General and administrative expenses	(20,465)	(21,662)	(18,065)	(16,817)	(17,280)
EBIT	23,981	32,438	36,900	33,737	22,227
Net financial expenses	(5,243)	(2,947)	(4,135)	(9,764)	(7,181)
Share in net profit of associates	221	1,127	1,220	3,701	613
EBT	18,959	30,618	33,984	27,674	15,659
Income tax	(4,453)	(5,896)	(8,203)	(6,561)	(3,631)
Net profit	14,506	24,722	25,782	21,113	12,027
EBITDA	39,829	47,939	52,850	48,666	36,467
EBITDA margin	17%	19%	22%	21%	18%

There were no special items in the above quarters.

3. Net Sales

	Q1 2026	Q1 2025
Sales by geographical segment:		
EMEA	124,256	101,471
Americas	88,660	85,171
APAC	19,479	16,144
Total	232,395	202,786
Sales by business segment:		
Prosthetics & Neuro Orthotics	135,711	111,142
Bracing & Supports	36,867	35,007
Internal product sales	(9,964)	(8,879)
External product sales	162,614	137,270
Patient Care	69,780	65,516
Total	232,395	202,786

Notes to the Condensed Consolidated Financial Statements

4. Sales and expenses split by main currencies

	LCY	Q1 2026	
		USD	%
Sales			
USD	77,934	77,934	34%
EUR	70,253	82,221	35%
ISK	107,989	871	0%
SEK, NOK, DKK		25,498	11%
GBP, AUD, CAD & Other		45,871	20%
Total		232,395	100%
COGS and OPEX			
USD	66,320	66,320	32%
EUR	55,599	65,071	31%
ISK	2,997,431	24,176	12%
SEK, NOK, DKK		23,810	11%
GBP, MXN, CAD & Other		29,037	14%
Total		208,414	100%
	LCY	Q1 2025	
		USD	%
Sales			
USD	76,462	76,462	38%
EUR	58,689	61,741	30%
ISK	132,981	961	0%
SEK, NOK, DKK		24,109	12%
GBP, AUD, CAD & Other		39,513	20%
Total		202,786	100%
COGS and OPEX			
USD	74,185	74,185	41%
EUR	40,065	42,149	23%
ISK	2,941,578	21,249	12%
SEK, NOK, DKK		23,019	13%
GBP, MXN, CAD & Other		19,957	11%
Total		180,559	100%

The currency split is derived based on the best available information at each reporting date.

Notes to the Condensed Consolidated Financial Statements

5. Property, plant and equipment

2026	Leasehold improvements	Machinery & equipment	Office equipment	Computer equipment	Total
Cost					
At 1 January	62,745	92,228	17,862	15,764	188,600
Additions	762	1,847	178	1,270	4,058
Eliminated on disposal	(253)	(65)	(37)	(30)	(386)
Fully depreciated assets	(11)	(151)	(502)	(24)	(688)
Exchange rate differences	(256)	(188)	(188)	(67)	(699)
At 31 March 2026	62,988	93,671	17,313	16,913	190,885
Depreciation					
At 1 January	27,086	58,810	12,175	10,315	108,385
Charge for the period	1,616	2,165	474	846	5,101
Eliminated on disposal	(213)	(61)	(22)	(33)	(329)
Fully depreciated assets	(11)	(151)	(502)	(24)	(688)
Exchange rate differences	(162)	(107)	(141)	(49)	(459)
At 31 March 2026	28,316	60,656	11,983	11,055	112,010
At 31 March 2026	34,672	33,015	5,330	5,858	78,875

Depreciation classified by functional category:	Q1 2026	Q1 2025
Cost of goods sold	2,362	2,613
Sales and marketing expenses	1,332	871
Research and development expenses	311	263
General and administrative expenses	1,096	866
Total	5,101	4,613

Notes to the Condensed Consolidated Financial Statements

6. Leases

Right of use assets

2026	Buildings & sites	Machinery & equipment	Total
At 1 January	157,857	4,658	162,514
Additions and renewals	7,186	0	7,186
Depreciation charge for the period	(6,763)	(757)	(7,519)
Eliminated on disposal and termination	(289)	0	(289)
Exchange rate differences	(1,352)	(88)	(1,440)
At 31 March 2026	156,638	3,813	160,452

Depreciation classified by functional category:	Q1 2026	Q1 2025
Cost of goods sold	2,654	2,583
Sales and marketing expenses	2,811	2,120
Research and development expenses	776	729
General and administrative expenses	1,278	1,308
Total	7,519	6,740

7. Goodwill

	31.3.2026	31.12.2025
At 1 January	835,560	776,306
Business combinations	281	18,698
Exchange rate differences	(7,630)	40,556
At end of period	828,211	835,560

Notes to the Condensed Consolidated Financial Statements

8. Other intangible assets

2026	Customer & distribution relationships	Patents & development costs	Trademarks	Software & other	Total
Cost					
At 1 January	47,559	34,163	8,627	69,448	159,798
Additions	0	16	0	205	221
Additions - internally generated	0	0	0	1,103	1,103
Exchange rate differences	(753)	(92)	(147)	(45)	(1,036)
At 31 March 2026	46,807	34,087	8,481	70,711	160,085
Amortization					
At 1 January	13,540	12,379	348	26,623	52,889
Charge for the period	1,054	614	70	1,490	3,228
Exchange rate differences	(150)	(38)	(9)	(28)	(225)
At 31 March 2026	14,444	12,955	408	28,085	55,893
At 31 March 2026	32,362	21,132	8,072	42,626	104,193
Amortization classified by functional category:				Q1 2026	Q1 2025
Cost of goods sold				162	245
Sales and marketing expenses				1,786	1,821
Research and development expenses				481	396
General and administrative expenses				799	426
Total				3,228	2,887